Page 34 - EFH 222

El Farmacéutico Hospitales. 2021; 222: 23-32 12. Goey AK, Sissung TM, Peer CJ, Trepel JB, Lee MJ, Tomita Y, et al. Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. J Clin Pharmacol. 2016; 56(4): 461-473. 13. Peer CJ, Goey AK, Sissung TM, Erlich S, Lee MJ, Tomita Y, et al. UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. J Clin Pharmacol. 2016; 56(4): 450-460. 14. Acrotech Biopharma LLC. Ficha técnica de Beleodaq (Belinostat). Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2020/761115s000lbl.pdf (Última consulta: diciembre 2020). 15. Ha VH, Jupp J, Tsang RY. Oncology drug dosing in Gilbert syndrome associated with UGT1A1: a summary of the literature. Pharmacotherapy. 2017; 37(8): 956-972. 16. Berrueco R, Alonso-Saladrigues A, Martorell-Sampol L, Català-Temprano A, Ruiz-Llobet A, Toll T, et al. Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening. Pediatr Blood Cancer. 2015; 62(7): 1.195-1.201. 17. Kishi S. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood. 2004; 103(1): 67-72. 18. Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006; 33(1): 50-67. 19. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001; 6(2): 162-176. 20. Liu Y, Ramírez J, House L, Ratain MJ. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos. 2010; 38(1): 32-39. 21. Gil J, Sąsiadek MM. Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism. Biomark Med. 2012; 6(2): 223-230. 22. Spraggs C, Budde L, Briley L, Bing N, Newstat B, Rappold E, et al. Hyperbilirubinemia in lapatinib treated patients is associated with Gilbert’s syndrome UGT1A1 Polymorphism. Cancer Res December. 2009; 69(24 Suppl): 1.112. 23. Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. Br J Cancer. 2010; 102(9): 1.371. 24. GlaxoSmithKline. Ficha técnica de Votrient® (pazopanib). Disponible en: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2012/022465s-010S-012lbl.pdf (Última consulta: diciembre 2020). 25. Ficha técnica de Votrient® (pazopanib). Disponible en: https:// cima.aemps.es/cima/dochtml/ft/10628001/FT_10628001.html (Última consulta: diciembre 2020). 26. Shibata T, Minami Y, Mitsuma A, Morita S, Inada-Inoue M, Oguri T, et al. Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. Int J Clin Oncol. 2014; 19(2): 391-396. 27. Bykova A, Abdullaev A, Gusarova G. Polymorphism of UGT1A1 and frequency of hyperbilirubinemia in patients with chronic myeloid leukemia treated by nilotinib. Blood. 2014; 124 (21): 5.538. 28. Patel P, Xue Z, King KS, ParhamL, Ford S, Lou Y, et al. Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir. J Antimicrob Chemother. 2020; 75(8): 2.240-2.248. 29. Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, et al. Gilbert’s disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology. 2006; 44(5): 1.324-1.332. 30. Ficha técnica de atazanavir. Disponible en: https://cima.aemps. es/cima/pdfs/es/ft/83678/83678_ft.pdf (Última consulta: febrero 2021). 31. Lankisch TO, Behrens G, Ehmer U, Möbius U, Rockstroh J, Wehmeier M, et al. Gilbert’s syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment. J Hepatol. 2009; 50(5): 1.010-1.018. 32. Douglas AP, Savage RL, Rawlins MD. Paracetamol (acetaminophen) kinetics in patients with Gilbert’s syndrome. Eur J Clin Pharmacol. 1978; 13: 209-212. 33. Ullrich D, Sieg A, Blume R, Bock KW, Schröter W, Bircher J. Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert’s syndrome. Eur J Clin Invest. 1987; 17(3): 237-240. 34. Esteban A, Pérez-Mateo M. Heterogeneity of paracetamol metabolism in Gilbert’s syndrome. Eur J Drug Metab Pharmacokinet. 1999; 24(1): 9-13. 35. Bernabeu I, Marazuela M, Lucas T, Loidi L, Álvarez-Escolá C, Luque-Ramírez M, et al. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome. J Clin Endocrinol Metab. 2010; 95(5): 2.147-2.154. 36. Bernabeu I, Cameselle-Teijeiro J, Casanueva FF, Marazuela M. Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert’s syndrome. Eur J Endocrinol. 2009; 160(5): 869-872. 37. Mallea-Gil MS, Bernabeu I, Spiraquis A, Avangina A, Loidi L, Ballarino C. Pegvisomant-induced cholestatic hepatitis in an acromegalic patient with UGT1A1*28 mutation. Case Rep Endocrinol. 2016; 2016: 2087102. 38. Tolomeo M, Colomba C, Meli M, Cascio A. Hepatotoxicity caused by mebendazole in a patient with Gilbert’s syndrome. J Clin Pharm Ther. 2019; 44(6): 985-987. 32 el farmacéutico hospitales n.o 222